Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H5NO4.C2H4NO2.Fe.H |
Molecular Weight | 261.998 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Fe++].NCC([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O
InChI
InChIKey=SITDSFUWDSKJII-JIZZDEOASA-L
InChI=1S/C4H7NO4.C2H5NO2.Fe/c5-2(4(8)9)1-3(6)7;3-1-2(4)5;/h2H,1,5H2,(H,6,7)(H,8,9);1,3H2,(H,4,5);/q;;+2/p-2/t2-;;/m0../s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
Title | Date | PubMed |
---|---|---|
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS. | 1932 Nov 11 |
|
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A. | 1932 Sep 30 |
|
[FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
[Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts. | 2014 |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/ferrous-salts.html
Unknown
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11169
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | |||
|
73415801
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | |||
|
644718
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
H7426RGB3L
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | |||
|
SUB130739
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | |||
|
H7426RGB3L
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY | |||
|
100000156746
Created by
admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD